Minakem-flap
Minakem-flap

Find Clinical Drug Pipeline Developments & Deals by Neurelis

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Therapeutic Area filter
    Study Phase filter
      Country filter
        News Type filter
          Company filter
            refresh

            Companies By Therapeutic Area Full Screen

            Development Status Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Diazepam

            Therapeutic Area: Neurology Product Name: Valtoco

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Cormorant Asset Management

            Deal Size: $114.0 million Upfront Cash: Undisclosed

            Deal Type: Series D Financing March 09, 2021

            Details:

            Funds will enhance growth and commercial penetration of company’s lead orphan drug product, VALTOCO® (diazepam nasal spray), and support pipeline development and expansion.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): NRL-4

            Therapeutic Area: Psychiatry/Psychology Product Name: NRL-4

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 23, 2020

            Details:

            NRL-4 is a proprietary formulation incorporating the science of Intravail®, which provides consistent and reliable absorption of medication via a proven, commercially available, single-use nasal sprayer.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Diazepam

            Therapeutic Area: Neurology Product Name: Valtoco

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 16, 2020

            Details:

            Data continue to support the unique clinical attributes for Neurelis' lead product, VALTOCO® (diazepam nasal spray), the first and only nasal spray treatment for seizure cluster rescue in pediatric patients 6 years of age and older, adolescents, and adults.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Diazepam

            Therapeutic Area: Neurology Product Name: Valtoco

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable September 23, 2020

            Details:

            Upon completion of the clinical study, Neurelis plans to submit a supplemental NDA (sNDA) with the FDA to expand VALTOCO's label to include patients aged 2 and older. Chambliss said the company plans to file the sNDA in 2021.